Functional Genomic mRNA Profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types

Oncotarget

Volumn 6, Issue 29, 2015, Pages 28164-28172

  Lamberts, Laetitia E ^a   de Groot, Derk Jan A ^a   Bense, Rico D ^a   de Vries, Elisabeth G E ^a   Fehrmann, Rudolf S N ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Antibody drug conjugate; Drug target; Functional genomic mRNA profiling; Mesothelin; Overexpression

Indexed keywords

MESOTHELIN; MESSENGER RNA; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; TUMOR MARKER;

ARTICLE; BREAST CANCER; ESOPHAGUS CANCER; FEMALE GENITAL TRACT CANCER; FUNCTIONAL GENOMICS; GASTROINTESTINAL TUMOR; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MESOTHELIN GENE; MICROARRAY ANALYSIS; NON SMALL CELL LUNG CANCER; ONCOGENE; PREDICTION; PROTEIN EXPRESSION; SYNOVIAL SARCOMA; THYROID CANCER; TUMOR DIFFERENTIATION; CLASSIFICATION; DNA MICROARRAY; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC DATABASE; GENETICS; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; PROGNOSIS; TRIPLE NEGATIVE BREAST CANCER;

BIOMARKERS, TUMOR; DATABASES, GENETIC; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GPI-LINKED PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84944462896     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4461     Document Type: Article

References (33)

1. Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int.J.Cancer. 1992; 50:373-381.
2. Bera TK, Pastan I. Mesothelin is not required for normal mouse development or reproduction. Mol.Cell.Biol. 2000; 20:2902-2906.
3. Hassan R, Laszik ZG, Lerner M, Raffeld M, Postier R, Brackett D. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am.J.Clin.Pathol. 2005; 124:838-845.
4. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin.Cancer Res. 2004; 10:3937-3942.
5. Frierson HF Jr, Moskaluk CA, Powell SM, Zhang H, Cerilli LA, Stoler MH, Cathro H, Hampton GM. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum.Pathol. 2003; 34:605-609.
6. Kachala SS, Bograd AJ, Villena-Vargas J, Suzuki K, Servais EL, Kadota K, Chou J, Sima CS, Vertes E, Rusch VW, Travis WD, Sadelain M, Adusumilli PS. Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma. Clin. Cancer Res. 2014; 20:1020-1028.
7. Tchou J, Wang LC, Selven B, Zhang H, Conejo-Garcia J, Borghaei H, Kalos M, Vondeheide RH, Albelda SM, June CH, Zhang PJ. Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res.Treat. 2012; 133:799-804.
8. Tozbikian G, Brogi E, Kadota K, Catalano J, Akram M, Patil S, Ho AY, Reis-Filho JS, Weigelt B, Norton L, Adusumilli PS, Wen HY. Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival. PLoS One. 2014; 9:e114900.
9. Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science. 2013; 341:1192-1198.
10. Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat.Rev.Drug Discov. 2007; 6:349-356.
11. Teicher BA, Chari RV. Antibody conjugate therapeutics: challenges and potential. Clin.Cancer Res. 2011; 17:6389-6397.
12. Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M, Kreitman RJ, Steinberg SM, Hollevoet K, Pastan I. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Cancer. 2014; 120:3311-3319.
13. Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, Onners B, Uram JN, Laheru DA, et al. Safety and survival with GVAX pancreas prime and Listeria monocytogenesexpressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J.Clin.Oncol. 2015; 33:1325-1333.
14. Curran KJ, Brentjens RJ. Chimeric antigen receptor T cells for cancer immunotherapy. J.Clin.Oncol. 2015; 33:1703-1706.
15. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, Kalos M, June CH. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer.Immunol.Res. 2014; 2:112-120.
16. Fehrmann RS, Karjalainen JM, Krajewska M, Westra HJ, Maloney D, Simeonov A, Pers TH, Hirschhorn JN, Jansen RC, Schultes EA, van Haagen HH, de Vries EG, te Meerman GJ, et al. Gene expression analysis identifies global gene dosage sensitivity in cancer. Nat.Genet. 2015; 47:115-125.
17. Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, Murugesan SR, Leach SD, Jaffee E, Yeo CJ, Cameron JL, Kern SE, Hruban RH. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin.Cancer Res. 2001; 7:3862-3868.
18. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am.J.Surg.Pathol. 2003; 27:1418-1428.
19. Ordonez NG, Sahin AA. Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study. Hum.Pathol. 2014; 45:1529-1540.
20. Kawamata F, Kamachi H, Einama T, Homma S, Tahara M, Miyazaki M, Tanaka S, Kamiyama T, Nishihara H, Taketomi A, Todo S. Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer. Int.J.Oncol. 2012; 41:2109-2118.
21. Kawamata F, Homma S, Kamachi H, Einama T, Kato Y, Tsuda M, Tanaka S, Maeda M, Kajino K, Hino O, Takahashi N, Kamiyama T, Nishihara H, et al. C-ERC/ mesothelin provokes lymphatic invasion of colorectal adenocarcinoma. J.Gastroenterol. 2014; 49:81-92.
22. Rizk NP, Servais EL, Tang LH, Sima CS, Gerdes H, Fleisher M, Rusch VW, Adusumilli PS. Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma. Cancer Epidemiol.Biomarkers Prev. 2012; 21:482-486.
23. Ito T, Kajino K, Abe M, Sato K, Maekawa H, Sakurada M, Orita H, Wada R, Kajiyama Y, Hino O. ERC/mesothelin is expressed in human gastric cancer tissues and cell lines. Oncol.Rep. 2014; 31:27-33.
24. Einama T, Homma S, Kamachi H, Kawamata F, Takahashi K, Takahashi N, Taniguchi M, Kamiyama T, Furukawa H, Matsuno Y, Tanaka S, Nishihara H, Taketomi A, et al. Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer. Br.J.Cancer. 2012; 107:137-142.
25. Zhao H, Davydova L, Mandich D, Cartun RW, Ligato S. S100A4 protein and mesothelin expression in dysplasia and carcinoma of the extrahepatic bile duct. Am.J.Clin.Pathol. 2007; 127:374-379.
26. Bauerschlag D, Brautigam K, Moll R, Sehouli J, Mustea A, Salehin D, Krajewska M, Reed JC, Maass N, Hampton GM, Meinhold-Heerlein I. Systematic analysis and validation of differential gene expression in ovarian serous adenocarcinomas and normal ovary. J.Cancer Res.Clin.Oncol. 2013; 139:347-355.
27. Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, Murugesan SR, Leach SD, Jaffee E, Yeo CJ, Cameron JL, Kern SE, Hruban RH. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin.Cancer Res. 2001; 7:3862-3868.
28. Weekes C, Lamberts LE, Borad MJ, Voortman J, McWilliams RR, Robinson Diamond J, de Vries EGE, Verheul HMW, Hanyoung Lieu C, Yue H, Wang Y, Scales S, Samineni D, et al. A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or platinum resistant ovarian cancer (OC). J Clin Oncol. ( suppl; abstr 2529).2014.
29. Bendell J, Blumenschein G, Zinner R, Hong D, Jones S, Infante J, Burris H, Rajagopalan P, Kornacker M, Henderson D, Kelly A, Hassan R. First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC), BAY 94-9343, in patients with advanced solid tumors. Cancer Res AACR abstract # LB-291. 2013.
30. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc.Natl.Acad.Sci.U.S.A. 2003; 100:8418-8423.
31. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J.Clin.Oncol. 2009; 27:1160-1167.
32. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006; 7:96.
33. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J.Clin.Invest. 2011; 121:2750-2767.